Comparative study of the efficacy and safety of 0.005 % Glaumax and 0.005 % Xalatan

   PURPOSE. To compare hypotensive efficiency and safety of generic latanoprost 0.005 % (Glaumax, “KEVELT AS”, Estonia) and original latanoprost 0.005 % (Xalatan, “Pfizer Inc”, USA) in glaucoma patients.
   METHODS.  The study included patients with newly diagnosed primary open-angle glaucoma or patients with primary open-angle glaucoma on carbonic anhydrase inhibitor monotherapy 4 days after cease of treatment (the “wash-out” period). Study patients were divided into 2 groups. Group 1 consisted of 25 patients (30 eyes) with initial and advanced stages of newly diagnosed POAG and initial corneal-compensated IOP (IOPcc) of 25.15 ± 1.48 mm Hg. This group of patients was prescribed instillations of 0.005 % Glaumax eye drops 1 time per day. Group 2 also included 25 patients (30 eyes) with initial stage of newly diagnosed POAG and initial corneal-compensated IOP (IOPcc) of 25.08 ± 1.42 mm Hg. Group 2 patients were prescribed instillations of 0.005 % Xalatan eye drops 1 time per day. IOPcc was measured initially after the washout period, then  1 and 2 months after the start of the new therapy. Additionally,  all patients were assessed for tear film break up time (Norn’s test) at each follow-up point.
   RESULTS.  After 1 month, IOPcc in groups 1 and 2 was 17.36 ± 1.39 and 18.09 ± 1.45 mm Hg, respectively; after 2 month, 17.87 ± 1.30 and 18.54 mm Hg, respectively. The Norn’s test results in groups 1 and 2 after 1 month were 8 (7; 9.75) and 8 (6; 9.75) seconds, after 2 months it was 8.5 (8; 9) and 8 (7; 10) seconds, respectively, which corresponded to the initial stage of the "dry eye" syndrome. No statistically significant intergroup differences were found in any of the cases.
   CONCLUSION. Xalatan 0.005 and Glaumax 0.005 have comparable efficacy and tolerability, and both help achieve persistent stabilization of IOP. The option for a single-instillation regimen is convenient for the patients.

1. Erichev V. P. Prostaglandins in ophthalmology. Vestnik oftal’mologii 2022; 138 (1): 107-114. https://doi.org/10.17116/oftalma2022138011107

2. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition. Savona: Italy PubliComm; 2014.

3. Natsional'noe rukovodstvo po glaukome dlya praktikuyushhikh vrachei. Izd. 4-e, ispravlennoe i dopolnennoe. [National glaucoma guidelines for practicing doctors. 4th edition]. Edited by: E. A. Egorov, V. P. Erichev. Moscow, GEOTAR-Media Publ., 2019. 384 p. (In Russ.)

4. Alekseev V. N., Malevannaya O. A. Estimation of dispensary supervision efficiency in patients withs primary open–angle glaucoma. RMJ Clinical Ophthalmology 2003; 4 (3): 119-122.

5. Makogon S. I., Makogon A. S. Analysis of the causes of low adherence to treatment in patients of primary open-angle glaucoma. Vestnik sovremennoy klinicheskoy meditsiny 2015; 6: 52-57.

6. Erichev V. P. Modern principles of antihypertensive therapy of glaucoma. Collection of scientific articles. Moscow, 2008: 220-223. (In Russ.)

7. Erichev V. P., Zinina V. S. Latanoprost in hypotensive therapy of glaucoma. Vestnik Oftal’mologii 2018; 134 (4): 91-99. https://doi.org/10.17116/oftalma201813404191.

8. Alekseev V. N., Levko M. A., Kalakhiri M. Efficacy and safety of xalatamax and xalatan at their use as open-angle glaucoma monotherapy. Oftalmologičeskie vedomosti 2013; 1: 11-15.

9. Chambers W. A. Ophthalmic generics: are they really the same. Ophthalmology 2012; 119 (6): 1095-1096.

10. Kuroyedov A. V., Ogorodnikova V. Yu., Aleksandrova L. A. Generics in glaucomatology: does the problem exist? Effective pharmacotherapy 2013; 23: 32-34.

11. Original drugs and generics of prostaglandin analogues in a hypotensive glaucoma therapy. Report on a scientific section of Russian glaucoma society. RMJ Clinical ophthalmology 2014; 14 (4): 236-238.